Companies › Criterium
3 active drug programs in 39 registered trials: 34 Phase 2, 4 Phase 1, 1 Phase 3; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Eribulin Tubulin inhibitor | Tubulin | Phase 2 | Breast Cancer | Jun 2027 |
| Trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 2 | Breast Cancer | Jun 2027 |
| Fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Colorectal Cancer; Metastatic Oesogastric Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma … | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05177068 | Fruquintinib | Phase 2 | Gastric Cancer | Oncology | Oct 2024 |
| NCT06446154 | Fruquintinib | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2025 |
| NCT06356584 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Oct 2026 |
| NCT06091423 | Fruquintinib | Phase 2 | Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Oncology | Nov 2026 |
| NCT06685276 | Fruquintinib | Phase 2 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT05954429 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Dec 2026 |
| NCT06484153 | Fruquintinib | Phase 2 | To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma | Oncology | Dec 2026 |
| NCT06356597 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Dec 2026 |
| NCT07491159 | Fruquintinib | Phase 1 | Colorectal Cancer | Oncology | Dec 2026 |
| NCT07257653 | Fruquintinib | Phase 2 | Colorectal Neoplasms | Oncology | Dec 2026 |
| NCT06774222 | Fruquintinib | Phase 2 | Gastric/Gastroesophageal Junction Adenocarcinoma | Oncology | Dec 2026 |
| NCT07334431 | Fruquintinib | Phase 1 | Gastric Adenocarcinoma | Oncology | Dec 2026 |
| NCT07011576 | Fruquintinib | Phase 2 | Colon Cancer | Oncology | Jan 2027 |
| NCT06979908 | Fruquintinib | Phase 2 | Metastatic Colorectal Cancer | Oncology | Jan 2027 |
| NCT05771181 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Feb 2027 |
| NCT06168786 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Feb 2027 |
| NCT06646588 | Fruquintinib | Phase 2 | Esophageal Neoplasms | Oncology | Apr 2027 |
| NCT06791083 | Fruquintinib | Phase 2 | Gastric Cancer | Oncology | May 2027 |
| NCT05458674 | Eribulin | Phase 2 | Breast Cancer | Oncology | Jun 2027 |
| NCT05458674 | Trastuzumab | Phase 2 | Breast Cancer | Oncology | Jun 2027 |
| NCT07920224 | Fruquintinib | Phase 2 | Stomach Neoplasms | Oncology | Jun 2027 |
| NCT05571644 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Aug 2027 |
| NCT07888309 | Fruquintinib | Phase 2 | Rectal Neoplasms | Oncology | Sep 2027 |
| NCT05831891 | Fruquintinib | Phase 2 | Non-clear Cell Renal Cell Carcinoma | Oncology | Oct 2027 |
| NCT07392346 | Fruquintinib | Phase 2 | Gastric Cancer Adenocarcinoma Metastatic | Oncology | Nov 2027 |
| NCT07136077 | Fruquintinib | Phase 2 | Minimal Residual Disease | Oncology | Dec 2027 |
| NCT07896096 | Fruquintinib | Phase 2 | Refractory Metastatic Colorectal Cancer | Oncology | Dec 2027 |
| NCT06889610 | Fruquintinib | Phase 2 | Triple Negative Breast Cancer Metastatic | Oncology | Dec 2027 |
| NCT06992258 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Dec 2027 |
| NCT06992258 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Dec 2027 |
| NCT07488533 | Fruquintinib | Phase 2 | Non-Clear Cell Renal Cell Carcinoma | Oncology | Dec 2027 |
| NCT06234007 | Fruquintinib | Phase 2 | Locally Advanced Rectal Cancer | Oncology | Dec 2027 |
| NCT07130903 | Fruquintinib | Phase 2 | Metastatic Colorectal Adenocarcinoma | Oncology | Apr 2028 |
| NCT06329973 | Fruquintinib | Phase 1 | Metastatic Gastroesophageal Junction Adenocarcinoma | Oncology | Jun 2028 |
| NCT07042685 | Fruquintinib | Phase 2 | Metastatic Colorectal Cancer (CRC) | Oncology | Dec 2028 |
| NCT06980532 | Fruquintinib | Phase 1 | Metastatic Colorectal Cancer | Oncology | Dec 2028 |
| NCT06441565 | Fruquintinib | Phase 2 | Colorectal Cancer | Oncology | Dec 2029 |
| NCT06856837 | Fruquintinib | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2029 |
| NCT07270991 | Fruquintinib | Phase 3 | Metastatic Oesogastric Adenocarcinoma | Oncology | Nov 2030 |
Ryvu Therapeutics GrandPharma (China) EpicentRx Elpiscience (Suzhou) Biopharma Pieris Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.